A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

Inclusion Criteria: * Written informed consent in accordance with institutional guidelines. If required by local law, candidates must also authorize the release and use of protected health information (PHI); * Adults of either gender 18-55 years of age at entry; * Healthy subjects as judged by the Investigator based on medical history, physical examination, and normal results for an ECG, CBC, serum chemistries, and urinalysis done up to 4 weeks prior to enrollment and administration of vaccination ± EP; * Current nonsmoker; * Women of child-bearing potential (WOCBP) agree to remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc), or have a partner who is sterile (i.e., vasectomy) until 12 weeks after last vaccination; * Able and willing to comply with all study procedures. Exclusion Criteria: * Positive serological test for Human Immunodeficiency Virus, hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or Grade 3 or greater CPK at screening; * Pregnant or breastfeeding subjects; * Any concurrent condition requiring the continued use of systemic or topical steroids at or near the injection site (excluding inhaled and eye drop-containing corticosteroids) or the use of other immunosuppressive agents. All other corticosteroids must be discontinued \> 4 weeks prior to Day 0 of study vaccine administration; * Administration of any blood product within 3 months of enrollment; * Prior receipt of any investigational or licensed H5N1 influenza vaccine at any time; * Subjects with contraindications to influenza vaccination other than egg allergy (such as a history of Guillain-Barre Syndrome after receiving influenza vaccine); * Administration of any vaccine within 6 weeks of enrollment; * Participation in a study with an investigational compound or device within 4 weeks of signing informed consent; * Subjects with cardiac pre-excitation syndromes (such as Wolff-Parkinson-White); * Subjects with a history of seizures (unless seizure free for 5 years); * Subjects with tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination ± EP; * Subjects with any implantable leads; * Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements; * Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness must not be enrolled into this study; * Any other conditions judged by the investigator that would limit the evaluation of a subject.